NCT06225804
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06225804
Title A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abbisko Therapeutics Co, Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Precision NextGen Oncology Beverly Hills California 90212 United States Details
Anhui Chest Hospital Hefei Anhui China Details
Fujian Cancer Hospital Fuzhou Fujian China Details
The first Affiliated Hospital of Xi'an Jiaotong University Xi'an Harbin China Details
Harbin Medical University Cancer Hospital Harbin Heilongjiang China Details
Henan Cancer Hospital Zhengzhou Henan China Details
Union Hospital Tongji Medical College Huzhong University of Science and Techology Wuhan Hubei China Details
Hunan Cancer Hospital Changsha Hunan China Details
The first Affiliated Hospital of Nanchang University Nanchang Jiangxi China Details
Jilin Cancer Hospital Changchun Jilin China Details
Central Hospital Affiliated to Shangdong of First Medical University Jinan Shandong China Details
Shanghai Chest Hospital Shanghai Shanghai Municipality China Details
Sichuan Cancer Hospital Chengdu Sichuan China Details
Zhejiang Caner Hospital Hangzhou Zhejiang China Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field